Cysteine protease cathepsins in atherosclerosis-based vascular disease and its complications.
about
Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitorsThe lysosome: from waste bag to potential therapeutic targetCirculating Anti-Elastin Antibody Levels and Arterial Disease Characteristics: Associations with Arterial Stiffness and AtherosclerosisNovel biological markers of bone: from bone metabolism to bone physiologyCathepsin L promotes Vascular Intimal Hyperplasia after Arterial InjuryIncreased serum cathepsin K in patients with coronary artery disease.Chemerin Elicits Potent Constrictor Actions via Chemokine-Like Receptor 1 (CMKLR1), not G-Protein-Coupled Receptor 1 (GPR1), in Human and Rat Vasculature.Serum cystatin C is a determinant of central pressure augmentation index measured by oscillometric method in renal transplant recipientsUrotensin II promotes atherosclerosis in cholesterol-fed rabbits.Cathepsin K-mediated Notch1 activation contributes to neovascularization in response to hypoxia.Increased Circulating Cathepsin K in Patients with Chronic Heart FailureIncreased Plasma Dipeptidyl Peptidase-4 Activities in Patients with Coronary Artery Disease.Increased Infiltration of Extra-Cardiac Cells in Myxomatous Valve Disease.Cysteinyl cathepsins: multifunctional enzymes in cardiovascular disease.Cysteine protease cathepsins and matrix metalloproteinases in the development of abdominal aortic aneurysms.Mechanisms with clinical implications for atrial fibrillation-associated remodeling: cathepsin K expression, regulation, and therapeutic target and biomarker.Cysteine protease inhibition by nitrile-based inhibitors: a computational study.Mast cell chymase and tryptase in abdominal aortic aneurysm formation.Odanacatib for the treatment of osteoporosis.Cathepsin L activity correlates with proteinuria in chronic kidney disease in humans.Insights from molecular modeling into the selective inhibition of cathepsin S by its inhibitor.MicroRNA regulation of extracellular matrix components in the process of atherosclerotic plaque destabilization.Cathepsin S Activity Controls Injury-Related Vascular Repair in Mice via the TLR2-Mediated p38MAPK and PI3K-Akt/p-HDAC6 Signaling Pathway.Cathepsin S Cleavage of Protease-Activated Receptor-2 on Endothelial Cells Promotes Microvascular Diabetes Complications.Cystatin C, chronic kidney disease and retinopathy in adults without diabetes.Changes in Structural-Mechanical Properties and Degradability of Collagen during Aging-associated ModificationsCorrelation of NLRP3 with severity and prognosis of coronary atherosclerosis in acute coronary syndrome patients.Cathepsin K activity controls injury-related vascular repair in mice.Decreased cathepsin K levels in human atherosclerotic plaques are associated with plaque instability.A possible role of cystatin C in adipose tissue homeostasis may impact kidney function estimation in metabolic syndrome.Cathepsin K activity controls cardiotoxin-induced skeletal muscle repair in mice.Cysteine Protease Cathepsins in Atherosclerotic Cardiovascular Diseases.Cathepsin S As an Inhibitor of Cardiovascular Inflammation and Calcification in Chronic Kidney Disease.Impact of circulating cathepsin K on the coronary calcification and the clinical outcome in chronic kidney disease patients.Genome-wide differential expression profiling of mRNAs and lncRNAs associated with prolificacy in Hu sheep.Differential hypertensive protease expression in the thoracic versus abdominal aorta.Live Cell Imaging and Profiling of Cysteine Cathepsin Activity Using a Quenched Activity-Based Probe.Dilating Vascular Diseases: Pathophysiology and Clinical AspectsInvestigating potential mediator between statin and coronary artery calcificationComparison of Different Measures of Fat Mass and Their Association with Serum Cystatin C Levels
P2860
Q26771736-0600F694-03E2-43A0-A955-239689516A1EQ27022248-E1A2D2ED-B4E3-4EC0-99E4-60F733A90D09Q27333137-3C52FA95-7798-4C46-90D8-572E265CE62DQ28067712-1370602E-D5A4-4D7C-B9AF-9104D7D04805Q33789216-49ABA52E-E701-43BE-8555-9883DEEB959BQ33822554-4237ADC9-4898-424D-AD00-DD8811B448ABQ34542663-5D2E3B49-EB3C-4971-A8F9-0B9609D561BDQ34940161-3E633583-62A7-4B44-8932-88265D13B6C6Q35152923-0BCC043A-8EBC-41A2-BF76-0F7B18A78531Q35181072-71B2390A-C667-4C94-B6DC-7FC6797B3EBCQ35753850-9922823A-818B-44B0-B2B7-5982ABD1189AQ36139664-806302A7-4E67-4E67-BCBE-7865E2FCBACEQ36155598-DAD24A95-AFD1-4668-9467-0855BDB45796Q36211889-D3C18380-6FA7-4EA8-8AD6-D060950B0288Q36599238-99FC9D2A-7E84-425C-98E3-EE50B7A3C09FQ37457719-2B6A844F-0BAC-42A1-9E72-AE71C022D5BFQ37696070-51F22359-2F1C-4F91-896C-5153B6B004F6Q38035575-85D3BBAD-07B7-4423-AEB1-99493F525D22Q38543387-418AE871-50E4-4167-BEC8-18A7C8617810Q38680372-8D0C2469-64B9-4ECE-8FED-A9999F63067FQ38943054-D8F87F17-2961-4D01-996E-63FC0D3C4BBBQ39261257-3E182F8C-16F4-48DA-AC7E-5FD65E5F1475Q39640572-CDC4BA8E-1124-494D-8E74-CC7114FB18EDQ40322521-68CC7990-FB74-455A-9F04-5467A28215DBQ40356301-39032FEB-F375-4F32-B0F8-D91CDA9DAA0DQ40679886-9FE5770F-64F3-4A4B-97E5-7B274718AD8BQ41468695-9DACA2F0-DD7B-4F1B-B6A9-B18BDAA7171FQ41769190-E901CC85-A1DE-4801-B906-DAB00B62D885Q42376295-AC476447-5021-4F6C-85F4-21BF43F3F6A4Q45236215-12AF9491-B2D3-4655-9427-CF61F4824D46Q47616758-0C3775C8-F1BD-4E16-B010-9EA1734D1934Q47696129-957A5AEC-D5E2-4A62-A194-99126763933FQ47696609-6893B6D0-14CF-4999-A662-5684A349D368Q48588869-3FD900D6-596C-465B-9811-5CEC4850B242Q50035213-CEF6244F-F180-4978-8C91-043E00FC6BFAQ50982477-8A1BFA84-7585-4273-91EA-A2FA4239A693Q52864120-77825FB2-67D6-48CC-9007-B85F5F63B0E8Q58702250-C19FDCBC-AA34-4F4C-A869-67009896D41AQ58727283-959B111A-0C34-40CE-9025-36BEAD337A0DQ59050709-9B1B9E9A-B41E-4480-9234-F52326BF6A16
P2860
Cysteine protease cathepsins in atherosclerosis-based vascular disease and its complications.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Cysteine protease cathepsins i ...... disease and its complications.
@en
Cysteine protease cathepsins i ...... disease and its complications.
@nl
type
label
Cysteine protease cathepsins i ...... disease and its complications.
@en
Cysteine protease cathepsins i ...... disease and its complications.
@nl
prefLabel
Cysteine protease cathepsins i ...... disease and its complications.
@en
Cysteine protease cathepsins i ...... disease and its complications.
@nl
P2093
P1433
P1476
Cysteine protease cathepsins i ...... disease and its complications.
@en
P2093
Kenji Okumura
Masafumi Kuzuya
Toyoaki Murohara
Xian Wu Cheng
P304
P356
10.1161/HYPERTENSIONAHA.111.180935
P407
P577
2011-10-10T00:00:00Z